Sociodemographic, disease, health system, and contextual factors affecting the initiation of biologic agents in rheumatoid arthritis: A longitudinal study

Arthritis Care and Research

Volumn 66, Issue 7, 2014, Pages 980-989

  Yelin, Edward ^a   Tonner, Chris ^a   Kim, Seoyoung C ^b   Katz, Jeffrey N ^b   Ayanian, John Z ^c   Brookhart, M Alan ^d   Solomon, Daniel H ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; STEROID;

ADULT; AGE; AGED; ARTHRALGIA; ARTICLE; COMMUNITY CARE; DEMOGRAPHY; ETHNICITY; FEMALE; HEALTH CARE ACCESS; HEALTH CARE DISPARITY; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HEALTH CENTER; HISPANIC; HOUSEHOLD; HUMAN; INCOME; INSURANCE; JOINT SWELLING; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MARRIED PERSON; PRESCRIPTION; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; RURAL AREA; SOCIAL STATUS; TELEPHONE INTERVIEW; URBAN AREA;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL FACTORS; DELIVERY OF HEALTH CARE; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; SOCIOECONOMIC FACTORS;

EID: 84903442785     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22244     Document Type: Article

References (24)

1. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-84.
2. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-39.
3. LaCaille D, Anis A, Guh D, Esdaile JM,. Gaps in care for rheumatoid arthritis: a population study. Arthritis Rheum 2005; 53: 241-8.
4. Schmajuk G, Schneeweiss S, Katz JN, Weinblatt ME, Setoguchi S, Avorn J, et al. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum 2007; 57: 928-34.
5. Schmajuk G, Trivedi AN, Solomon DH, Yelin E, Trupin L, Chakravarty EF, et al. Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans. JAMA 2011; 305: 480-6.
6. Solomon DH, Ayanian JZ, Yelin E, Shaykevich T, Brookhart MA, Katz JN,. Use of disease-modifying medications for rheumatoid arthritis by race and ethnicity in the National Ambulatory Medical Care Survey. Arthritis Care Res (Hoboken) 2012; 64: 184-9.
7. Tavares R, Pope JE, Tremblay JL, Thorne C, Bykerk VP, Lazovskis J, et al. Early management of newly diagnosed rheumatoid arthritis by Canadian rheumatologists: a national, multicenter, retrospective cohort. J Rheumatol 2011; 38: 2342-5.
8. Tavares R, Pope JE, Tremblay JL, Thorne C, Bykerk VP, Lazovskis J, et al. Time to disease-modifying antirheumatic drug treatment in rheumatoid arthritis and its predictors: a national, multicenter, retrospective cohort. J Rheumatol 2012; 39: 2088-97.
9. Chu LH, Portugal C, Kawatkar AA, Stohl W, Nichol MB,. Racial/ethnic differences in the use of biologic disease-modifying antirheumatic drugs among California Medicaid rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2013; 65: 299-303.
10. Putrik P, Ramiro S, Kvien T, Sokka T, Pavlova M, Uhlig T, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 2014; 73: 198-206.
11. Kawachi I, Subramanian SV, Almeida-Filho N,. A glossary for health inequalities. J Epidemiol Community Health 2002; 56: 647-52.
12. Braveman PA,. Monitoring equity in health and healthcare: a conceptual framework. J Health Popul Nutr 2003; 21: 181-92.
13. Yelin E, Henke C, Kramer J, Nevitt MC, Shearn M, Epstein WV,. A comparison of the treatment of rheumatoid arthritis in health maintenance organizations and fee-for-service practices. N Engl J Med 1985; 312: 962-7.
14. Yelin E, Criswell L, Feigenbaum P,. Health care utilization and outcomes among persons with rheumatoid arthritis in fee-for-service and prepaid group practices. J Am Med Assoc 1996; 276: 1048-53.
15. Katz PP, Morris A, Yelin EH,. Prevalence and predictors of disability in valued life activities among individuals with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 763-9.
16. Center for the Evaluative Clinical Sciences at Dartmouth Medical School. Dartmouth Atlas of Health Care. Lebanon (NH): Dartmouth Medical School; 2004.
17. U.S. Bureau of the Census. Design and methodology: American Community Survey. Washington, DC: U.S. Government Printing Office; 2009.
18. Venkateshan SP, Sidhu S, Malhotra S, Pandhi P,. Efficacy of biologicals in the treatment of rheumatoid arthritis: a meta-analysis. Pharmacology 2009; 83: 1-9.
19. Kuriya B, Arkema EV, Bykerk VP, Keystone EC,. Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta- analysis of clinical and radiographic remission. Ann Rheum Dis 2010; 69: 1298-304.
20. Cook NL, Hicks LS, O'Malley AJ, Keegan T, Guadagnoli E, Landon BE,. Access to specialty care and medical services in community health centers. Health Aff (Millwood) 2007; 26: 1459-68.
21. Mehrotra A, Forrest CB, Lin CY,. Dropping the baton: specialty referrals in the United States. Milbank Q 2011; 89: 39-68.
22. Goldman D, Joyce G, Lawless G, Crown WH, Willey V,. Benefit design and specialty drug use. Health Aff (Millwood) 2006; 25: 1319-31.
23. Barton JL, Imboden J, Graf J, Glidden D, Yelin EH, Schillinger D,. Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010; 62: 857-64.
24. Fraenkel L, Peters E, Charpentier P, Olsen B, Errante L, Schoen RT, et al. Decision tool to improve the quality of care in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 977-85.